We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Nora Möhn

Nora D. Möhn MD

Department of Neurology, Hannover Medical School; Immune Cooperative Oncology Group (ICOG), Comprehensive Cancer Center Niedersachsen (CCCN), Hannover, Germany

Dr. Nora Möhn is resident at the Department of Neurology at Hannover Medical School. After a study abroad in St Gallen, Switzerland, she received her medical degree from Hannover Medical School. Her research studies focus on improving the care of patients receiving oncological immunotherapies. The main area of interest is the investigation of neurological adverse events during immune checkpoint inhibitor therapy and CAR T cell therapy. Together with colleagues from Hannover Medical School she founded the Immune Cooperative Oncology Group (ICOG) which is responsible for interdisciplinary care and comprehensive investigation of patients treated with immune checkpoint inhibitors. In addition, she is involved in the implementation of innovative treatment strategies for patients suffering progressive multifocal leukoencephalopathy (PML).